Posted on

Core One Labs’ Akome Biotech Initiates Neurogenesis Stimulation and Modeling Studies: Advancing its Proprietary Psychedelic-based Pharmaceutical Formulations

Core One Labs’ Akome Biotech Initiates Neurogenesis Stimulation and Modeling Studies: Advancing its Proprietary Psychedelic-based Pharmaceutical Formulations

Vancouver, British Columbia, Canada – March 4, 2022 – Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”) is pleased to announce that its wholly owned subsidiary Akome Biotech Ltd. (“Akome”), has entered into an agreement with the Universidad Complutense de Madrid (“Universidad Complutense”), officially commencing neurogenesis stimulation and modelling studies research, to advance the development of the Company’s patent pending psychedelic bioactive compounds that target Alzheimer’s Disease, Parkinson’s Disease, Major Depressive Disorder and Ischemic Stroke.

Neurogenesis is the ability of the brain to grow new neurons. Until recently, neuroscientists believed that the central nervous system, including the brain, was incapable of neurogenesis and unable to regenerate. However, research conducted over the last two decades confirms, not only that adult neurogenesis is a normal process that occurs in the healthy brain, but also that it can be enhanced by psychedelics among other potent stimulants. Neurogenesis is considered important in neuroplasticity, the ability of the brain to form new connections and pathways and change how its circuits are wired. Through Akome’s initial data mapping of how psychedelic substances and selected bioactive substances cooperate, there is potential for significant stimulus in adult neurogenesis in the brains of individuals that are afflicted with certain neurological disorders, and Akome’s research with Universidad Complutense seeks to prove that its chosen bioactive-compounds can enhance such processes.

The research, which is currently underway, is being led by Dr. Jose A. Morales-Garcia, PhD, of the Universidad Complutense de Madrid, a leading institution with extensive experience in psychedelics research, and neurodegenerative processes responsible for conditions such as Alzheimer’s disease, Major Depressive disorder, Parkinson’s disease and ischemic stroke. The scope of research is designed to advance the Company’s hypothesis that the selected candidate bioactive compounds included in its patent submissions, are viable candidates and will react positively upon targets in the Central Nervous System, and have the potential to stimulate neurogenesis in the brain of individuals afflicted with neurological disorders, and subsequently result in groundbreaking clinical implications for the indications of Ischemic stroke, Alzheimer’s disease, Major Depressive disorder and Parkinson’s disease.

Dr. Morales is an Assistant Professor and Honorary fellow in the Cellular Biology Department at the Complutense University of Madrid, Medical School, a scientist at the Center for Networked Biomedical Research on Neurodegenerative Diseases, as well as a professor in the Master of Pharmacological Research at the Autonoma University of Madrid. Dr. Morales has over 40 scientific publications in peer-reviewed journals.

Dr. Morales’ has vast research background in the identification and analysis of new cellular targets implicated in neurogenesis and neurodegeneration as well as focused work in the study in vitro and in vivo of the mechanism underlying neurodegenerative disease, mainly Alzheimer´s and Parkinsonism in order to develop new neuroprotective, anti-inflammatory and neurogenic compounds for the treatment of these disorders.

“I believe that the treatment of individuals with neurological disorders through the use of psychedelic based pharmaceuticals, will become a major focus of mental healthcare in the near future. The groundbreaking work that Universidad Complutense is doing for Akome, will contribute significantly to the advancement of our drug formulations as we work to commercialize our patents. By developing unique psychedelic based pharmaceutical formulations that can be used for the treatment of Alzheimer’s, Parkinson’s, Depression and Ischemic Stroke, the Company is positioning itself to serve a larger and more diverse patient base,” stated Joel Shacker, the Company’s CEO.

About Core One Labs Inc.

Core One is a biotechnology research and technology life sciences enterprise focused on bringing psychedelic medicines to market through novel delivery systems and psychedelic assisted psychotherapy. Core One has developed a patent pending thin film oral strip (the “technology”) which dissolves instantly when placed in the mouth and delivers organic molecules in precise quantities to the bloodstream, maintaining excellent bioavailability. The Company intends to further develop and apply the technology to psychedelic compounds, such as psilocybin. Core One also holds an interest in medical clinics which maintain a combined database of over 275,000 patients. Through these clinics, the integration of its intellectual property, R&D related to psychedelic treatments and novel drug therapies, the Company intends to obtain regulatory research approval for the advancement of psychedelic-derived treatments for mental health disorders.

Core One Labs Inc.

Joel Shacker

Chief Executive Officer

FOR MORE INFORMATION, PLEASE CONTACT:

info@core1labs.com

1-866-347-5058

Cautionary Disclaimer Statement:

The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management’s current estimates, beliefs, intentions, and expectations. They are not guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain, and that actual performance may be affected by a number of material factors, many of which are beyond the Company’s control. Such factors include, among other things: risks and uncertainties relating to the Company’s limited operating history and the need to comply with strict regulatory regulations.  Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.

In addition, psilocybin is currently a Schedule III drug under the Controlled Drugs and Substances Act (Canada) and it is a criminal offence to possess substances under the Controlled Drugs and Substances Act (Canada) without a prescription or authorization. Health Canada has not approved psilocybin as a drug for any indication. Core One does not have any direct or indirect involvement with illegal selling, production, or distribution of psychedelic substances in jurisdictions in which it operates. While Core One believes psychedelic substances can be used to treat certain medical conditions, it does not advocate for the legalization of psychedelics substances for recreational use. Core One does not deal with psychedelic substances, except within laboratory and clinical trial settings conducted within approved regulatory frameworks.

Posted on

Core One Labs Announces Successful Proof-of-Concept for Biosynthetic N-methyltryptamine (NMT)

Core One Labs Announces Successful Proof-of-Concept for Biosynthetic N-methyltryptamine (NMT)

VANCOUVER, British Columbia, March 3, 2022 – Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (“Core One” or the “Company”), is pleased to announce that its wholly owned subsidiary, Vocan Biotechnologies Inc. (“Vocan”), has successfully tested its proof-of-concept for the production of biosynthetic N-methyltryptamine (NMT) (also known as monomethyl tryptamine (MMT)) for use in future upscaling capabilities. NMT, which belongs to the family of tryptamines, is an organic alkaloid compound known to produce psychoactive effects when combined with a monoamine oxidase A inhibitor (MAOI).[1]

The proof-of-concept procedure assessed the Company’s proprietary Recombinant Production System for the biosynthesis of psilocybin and bioidentical psychedelic analogs and proved feasible for mass production.

The project, led by Dr. Jan Burian, Chief Scientist, and Dr. Robert EW Hancock, Vocan CEO, had Vocan’s team of scientists optimized DNA sequences that can produce enzymes replicating the biosynthetic pathways used by Psilocybe mushrooms, combined with enhanced enzymes from bacteria and animals. The method makes use of a gene mimicry process and simple enzyme-guided chemical modifications to formulate bioidentical compounds and novel analogs of psilocybin and related psychedelics such as NMT. The analog compounds, being synthetic in nature, have the potential to be more effective and safer than the natural compounds.

Core One’s proprietary Recombinant Production System aims to reshape the psychedelic industry by providing cGMP compliant biosynthetic psychedelic compounds and analogs in large volumes and quicker turnaround time. The psychedelic industry currently utilizes chemically synthesized psilocybin when it comes to large quantities and commercial use.

The success of Core One’s System can assist in cutting down the cost of synthetic psilocybin and related psychedelic compounds drastically while also maintaining its high level of efficacy and quality, similar to that found in organically produced psychedelics. Such a breakthrough marks Core One Labs as a major player in the psychedelic sector and makes its product portfolio unrivaled amongst its competitors.

“This has demonstrated that our technology has much broader implications in producing psychoactive drugs other than psilocybin, which we previously announced we could successfully make in our recombinant production system. Both processes have been filed for patent protection,” stated Dr. Robert Hancock, Vocan CEO.

ABOUT CORE ONE LABS INC.

Core One is a biotechnology research and technology life sciences enterprise focused on bringing psychedelic medicines to market through novel delivery systems and psychedelic assisted psychotherapy. Core One has developed a patent pending thin film oral strip (the “technology”) which dissolves instantly when placed in the mouth and delivers organic molecules in precise quantities to the bloodstream, maintaining excellent bioavailability. The Company intends to further develop and apply the technology to psychedelic compounds, such as psilocybin. Core One also holds an interest in medical clinics which maintain a combined database of over 275,000 patients. Through these clinics, the integration of its intellectual property, R&D related to psychedelic treatments and novel drug therapies, the Company intends to obtain regulatory research approval for the advancement of psychedelic-derived treatments for mental health disorders.

CORE ONE LABS INC.

Joel Shacker

Chief Executive Officer

FOR FURTHER INFORMATION:

Email: info@core1labs.com

Telephone: 1-866-347-5058

FOLLOW US:

Website: https://core1labs.com/

Twitter: https://twitter.com/Coreonelabs

Facebook: https://www.facebook.com/Core-One-Labs-Inc-100969251278277/

LinkedIn: https://www.linkedin.com/company/core-one-labs

Instagram: https://www.instagram.com/coreonelabsinc/

CAUTIONARY DISCLAIMER STATEMENT

The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management’s current estimates, beliefs, intentions, and expectations. They are not guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain, and that actual performance may be affected by a number of material factors, many of which are beyond the Company’s control. Such factors include, among other things: risks and uncertainties relating to the Company’s limited operating history and the need to comply with strict regulatory regulations. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.

In addition, psilocybin is currently a Schedule III drug under the Controlled Drugs and Substances Act (Canada) and it is a criminal offence to possess substances under the Controlled Drugs and Substances Act (Canada) without a prescription or authorization. Health Canada has not approved psilocybin as a drug for any indication. Core One does not have any direct or indirect involvement with illegal selling, production, or distribution of psychedelic substances in jurisdictions in which it operates. While Core One believes psychedelic substances can be used to treat certain medical conditions, it does not advocate for the legalization of psychedelics substances for recreational use. Core One does not deal with psychedelic substances, except within laboratory and clinical trial settings conducted within approved regulatory frameworks.

[1] Foye’s principles of medicinal chemistry By William O. Foye, Thomas L. Lemke, David A. Williams

Posted on

Field Trip Health and Cerebral Partner to Provide End-to-End Mental Health Care

Field Trip Health and Cerebral Partner to Provide End-to-End Mental Health Care

The pioneer psychedelic therapy company is partnering with the rapidly growing online mental health platform to create a comprehensive mental health offering for consumers

TORONTO, March 3, 2022 /PRNewswire/ — Field Trip Health Ltd. (NASDAQ: FTRP, TSX: FTRP) (“Field Trip”), a global leader in the development and delivery of psychedelic-assisted psychotherapy, today announced a strategic partnership with Cerebral, the fastest growing online mental health platform. The companies are launching a partnership where Cerebral clinicians can refer qualified clients to Field Trip Health’s ketamine assisted therapy, while Field Trip will connect potential clients seeking general psychiatry and teletherapy services to Cerebral. This end-to-end solution will provide personalized treatment solutions for those seeking to improve their mental health.

Field Trip Health currently has clinics operating in eight major U.S. cities, making it the largest provider of psychedelic-assisted therapies in North America. With this partnership, Field Trip Health patients will have access to services beyond psychedelic treatments and can now access a holistic offering of mental health treatments through Cerebral.

“Our partnership with Cerebral will lower the barriers of entry into ketamine assisted therapy for many people who have solely been exposed to generalized psychiatry or might have not been presented with an alternative of exploring a healing journey propelled through psychedelics,” said Ronan Levy, Field Trip’s Executive Chairman. “We’re excited to be Cerebral’s preferred platform to refer patients to. Together we will help change the mental health landscape by bringing together teletherapy, telepsychiatry, and psychedelic-assisted therapy and offer more comprehensive benefits to consumers’ mental health.”

Cerebral’s mission is to improve access to long-term, high-quality comprehensive mental health care through affordable plans on their online mental health platform which provides comprehensive care including therapy, counseling, and medication management. Cerebral’s platform allows members to schedule and meet with their care team online and provides medication management and delivery straight to your door.

“The recent shift in the mental health landscape has resulted in a need for modernized, digitized, and personalized solutions. At its core, Cerebral believes that everyone deserves access to individualized, non-judgmental mental health care,” added Dr. David Mou, Cerebral’s Chief Medical Officer. “We’re constantly searching for novel ways to work towards that goal, which is why we chose to partner with Field Trip, a like-minded company with an aligning ethos that brings psychedelic-assisted psychotherapy to the table for our clients,”

About Field Trip Health Ltd.

Field Trip is a global leader in the development and delivery of psychedelic therapies. With our Field Trip Discovery division leading the development of the next generation of psychedelic molecules and conducting advanced research on plant-based psychedelics and our Field Trip Health division building centers for psychedelic therapies opening across North America and Europe along with the digital and technological tools that will enable massive scale, we help people in need with a simple, evidence-based way to heal and heighten engagement with the world.

Learn more at: www.fieldtriphealth.com

Follow us on Twitter and Instagram: @fieldtriphealth

About Cerebral

Cerebral’s mission is simple and straightforward: To improve access to long-term, high-quality mental health care to all. Unlike traditional mental health care, Cerebral is accessible, convenient, affordable, and free of stigma. With several full-service monthly subscription plans to choose from, members receive online access to prescribing providers, behavioral counselors, and talk therapists—all from the comfort of home or anywhere else with an internet connection. Visits are done via video chat, and members can message their care team directly. Members can even receive medications delivered straight to their door (if prescribed). Cerebral was founded and launched in January 2020 by CEO Kyle Robertson. For more information, visit www.cerebral.com

To receive company updates about Field Trip and to be added to the email distribution list please sign up here.

Cautionary Note Regarding Forward-Looking Information.

This release includes forward-looking information (within the meaning of Canadian securities laws and within the meaning of the United States Private Securities Litigation Reform Act of 1995) regarding Field Trip and its business. Often but not always, forward-looking information can be identified by the use of words such as “expect”, “intends”, “anticipated”, “believes” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would” or “will” be taken, occur or be achieved. Such statements are based on the current expectations and views of future events of the management of Field Trip, and are based on assumptions and subject to risks and uncertainties. Although the management of Field Trip believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the companies, including commencement, uptake and success of the referral relationship between Cerebral and Field Trip, factors affecting the medical clinic industry, market conditions, economic factors, management’s ability to manage and to operate the business and the equity markets generally. Although Field Trip has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Field Trip does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. For a more detailed discussion of risks and other factors, see Field Trip’s amended Annual Information Form dated July 16, 2021 under the heading “Risk Factors”, or otherwise disclosed in the public filings made with applicable securities regulatory authorities and available under Field Trip’s SEDAR and EDGAR profiles.

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities.

Neither the Toronto Stock Exchange nor its Regulation Services Provider, have approved the contents of this release or accept responsibility for the adequacy or accuracy of this release.

CisionView original content to download multimedia:https://www.prnewswire.com/news-releases/field-trip-health-and-cerebral-partner-to-provide-end-to-end-mental-health-care-301494788.html

SOURCE Field Trip Health

Posted on

Telescope Provides A Corporate Update

Telescope Provides A Corporate Update

Vancouver, BC — March 1, 2022 — Telescope Innovations Corp. (“Telescope” or the “Company”) (CSE: TELI), a chemical technology company, is pleased to provide a corporate update summarizing the significant milestones the Company has achieved over the past year of operations. The rapidly growing Company has delivered on the following three milestones that it believes set the foundation for unlocking future value for shareholders:

  1. Established a growing intellectual property portfolio on pharmaceutical manufacturing,
  2. Increased in-house research capacity and proprietary research platforms, and;
  3. Brought in award winning scientific leadership.

“In a little over a year, we have established Telescope as a deep tech company applying innovative chemistry technology to challenges in the pharmaceutical industry.” Said Jason Hein, CEO of Telescope. “We have discovered novel, scalable routes to manufacture psilocybin and address a huge unmet need in the treatment of mental health. Beyond this application, we are developing a robust set of technology platforms that accelerate chemistry research by leveraging robotic automation and artificial intelligence. We look forward to building out from this core foundation and deploying our systems to meet the biggest challenges in healthcare and chemical manufacturing.”

1. Established a growing intellectual property portfolio valuable for pharmaceutical manufacturing

One of Telescope’s strategic aims is to capitalize on the demand for the pharmaceutical-grade psychedelic therapeutics that are poised to address a growing US$ 16 billion market in anxiety disorders and depression treatment. While demand is growing, there is currently no regulated safe supply of psilocybin for therapeutic use. The Company has therefore focused on developing proprietary, scalable synthetic processes compatible with current good manufacturing practices (“cGMP”), with a view to sell and/or license this intellectual property to pharmaceutical companies or therapeutic providers.

Telescope has built out an intellectual property portfolio that currently consists of synthetic routes for the scalable production of pharmaceutical-grade psilocybin and psilocin (the active chemicals in psychedelic mushrooms) as well as their molecular precursors, analogs, and derivatives. These routes, in addition to a group of novel chemical entities, are captured in a Patent Cooperation Treaty Application (“PCT”) filed by Telescope in December 2021. 

Telescope’s proprietary chemical manufacturing methods have several key advantages (Figure 1):

  • They require fewer synthetic steps than other available methods, reducing supply chain costs, waste streams, and investments in the isolation and purification of intermediate compounds. Shorter manufacturing cycles also accelerate deployment and help maintain a competitive position.
  • Unlike existing synthetic methods, we avoid the use of highly flammable chemicals that are prohibitively hazardous at a large scale.
  • We combine chemical manufacturing techniques that are standard practice in the pharmaceutical industry. This feature lowers the development costs to deploy our synthetic route and enables faster profitability.

Figure 1. Short, safe synthetic processes using industry-friendly methods (such as Telescope’s proprietary routes to psilocybin) provide significant economic benefits for commercial manufacturing.

  • Our manufacturing routes are purposely flexible and easily tunable to produce valuable compounds in the same chemical family (e.g., dimethyltryptamine, harmaline, miprocin, ibogaine, melatonin, lysergic acid diethylamide, serotonin, bufotenine, etc.). The routes can also be tailored to produce novel molecules that may increase the safety, potency, or bioactivity of new psychedelic therapeutics. Even if a specific chemical compound fails to achieve FDA approval or pass regulatory milestones, Telescope’s manufacturing route can rapidly pivot to target the next generation of psychedelic drug candidates.

Within the PCT application filed in December 2021, Telescope has also captured a set of novel chemical entities (“NCEs”) to build a proprietary library of psychoactive compounds. The newly discovered molecules may perform similarly or more efficiently than psilocybin or other psychedelic medicines, and may become candidates for preclinical development as next-generation therapeutics in the future (Figure 2). NCEs may display improvements in safety, potency, specificity, or tunability, for example. To evaluate this potential, Telescope will pursue biological testing of these proprietary compounds by third-party, world-leading neurochemistry experts. Initial testing will aim to establish the effectiveness of the NCEs relative to leading psychoactive candidates.

Figure 2. Telescope’s intellectual property portfolio includes a set of novel chemical entities in the same chemical family as psilocybin. These new compounds may pave the way for accessing the next generation of psychedelic therapeutics.

Telescope plans to expand this intellectual property moat over the next year to increase the scope of proprietary chemical reactivity and accessible products. The Company is also building relationships with biotechnology and pharmaceutical companies to explore avenues for monetization.

–back to top–

2. Increased in-house research capacity and proprietary research platforms

As of June 2021, Telescope occupies a dedicated laboratory facility in Vancouver, British Columbia. Here, we are developing and deploying our unique, proprietary ReACT platforms (Figures 3 and 4): robotic systems guided by artificial intelligence that increase the efficiency and quality of chemical research. We combine and integrate automation systems into a next-generation, self-guided chemistry experimentation platform that provides rapid, reliable data. This approach to research has enabled us to develop Telescope’s synthetic manufacturing processes for psilocybin in under one year.

Figure 3. Telescope’s ReACT platforms dramatically accelerate chemistry research.

ReACT is powered by our cross-disciplinary technical team of organic, process, and analytical chemists, computer scientists, and mechatronics engineers. The seamless integration of hardware, software, and chemistry knowledge is key to rapidly advancing Telescope’s technical goals.

Figure 4. A robotic arm module used in Telescope’s ReACT platforms.

Telescope’s high-level aim is to transform industrial research and development by deploying its automated platforms and chemical technology across the pharmaceutical and chemical manufacturing sectors. Over the next quarter, we aim to engage in consulting agreements and research contracts with specific, major global pharmaceutical and chemical manufacturing companies to apply our research platforms in industrial settings. These projects would generate near term cash flow while validating Telescope’s ability to break down process barriers and increase the efficiency of industrial R&D. We are also exploring relationships with global laboratory instrumentation and automation companies to commercialize Telescope’s automation platforms, aiming to manufacture, market, and sell these platforms over the next two years.

–back to top–

3. Brought in award-winning scientific leadership

Telescope’s technical leadership comprises internationally renowned experts in chemical manufacturing and automation, having collectively authored over 450 academic publications and 33 patents. 

  • Prof. Barry Sharpless (Senior technical advisor) received the Nobel Prize in Chemistry in 2001 for “the most important discovery in the field of synthesis during the past few decades”.  He received the Priestley Medal (the highest honour in the American Chemical Society) in 2019 and is the W.M. Keck Professor of Chemistry at the Scripps Research Institute in La Jolla, California.
  • Prof. Jason Hein (CEO, Director) leads one of the largest academic chemistry research groups in Canada at the University of British Columbia. Has authored 50+ peer-reviewed articles amassing over 4,000 citations on organic chemistry, commercial manufacturing, and the role of automation, robotics and artificial intelligence in controlling pharmaceutical production.

–back to top–

About Telescope

Telescope is a chemical technology company developing scalable manufacturing processes and tools for the pharmaceutical and chemical industry. The Company builds and deploys new enabling technologies including flexible robotic platforms and artificial intelligence software that improves experimental throughput, efficiency, and data quality. A key area of application for these tools is the development of scalable manufacturing processes for mental health medicines in the under-utilized tryptamine class of compounds, including psychedelic therapeutics. Our aim is to bring modern chemical solutions to meet the most serious challenges in human health. 

On behalf of the Board,

Telescope Innovations Corp.

Jason Hein, Chief Executive Officer

E: jason@telescopeinn.com 

Forward-Looking Information

Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by the Company as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to the factors described in greater detail in the “Risk Factors” section of the prospectus filed by the Company and available at www.sedar.com. 

Forward-looking statements in this document include expectations surrounding revenue streams from the research agreements, the patent filing process and the timing thereof, uses and viability of the intellectual property portfolio held by the Company, the performance of novel chemical entities, anticipated trends in the demand for psychedelic medical treatments and the ability of the intellectual property portfolio of the Company to respond to this demand, and all other statements that are not statements of historical fact.   

Examples of such assumptions, risks and uncertainties include, without limitation, assumptions, risks and uncertainties associated with the global COVID-19 pandemic, including the risk that the Company be deemed a non-essential business and asked to temporarily cease operations; general economic conditions; adverse industry events; future legislative and regulatory developments involving psilocybin; the Company’s ability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favorable terms; the psilocybin industry in Canada and generally; the ability of the Company to implement its business strategies; competition; and other assumptions, risks and uncertainties.

These factors are not intended to represent a complete list of the factors that could affect the Company; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

The CSE has neither approved nor disapproved the contents of this news release. Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Posted on

Seelos Therapeutics Announces Dosing of the First Participants in a Registrational Phase II/III Trial of SLS-005 in Amyotrophic Lateral Sclerosis on the HEALEY ALS Platform

Seelos Therapeutics Announces Dosing of the First Participants in a Registrational Phase II/III Trial of SLS-005 in Amyotrophic Lateral Sclerosis on the HEALEY ALS Platform

NEW YORK, Feb. 28, 2022 /PRNewswire/ — Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced the dosing of the first participants in its registrational Phase II/III trial studying the investigational treatment SLS-005 (trehalose injection, 90.5 mg/mL for intravenous infusion) for the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease) on the HEALEY ALS Platform Trial.

“Initiating this trial is a major achievement for Seelos and we are honored to be part of the HEALEY ALS Platform Trial. We look forward to offering this investigational therapy to people suffering with this debilitating disease,” said Raj Mehra Ph.D., Chairman and CEO of Seelos.  

“We are thankful to all the patients with ALS who participate in the HEALEY ALS Platform Trial and help develop new treatments in a much faster and more efficient approach.  Partnering with Seelos to determine the efficacy of SLS-005 in this platform trial will give answers sooner because of the sharing of data and infrastructure with other regimens in the platform trial,” added Merit Cudkowicz, MD, director of the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital, Chief of the Department of Neurology, and Principal Investigator of the HEALEY ALS Platform Trial.

Seelos’ Phase II/III trial (NCT05136885) plans to enroll 160 participants with either familial or sporadic ALS in a double-blind placebo-controlled trial. Participants will be randomized 3:1 (drug: placebo) and studied with a primary endpoint measuring change from baseline on Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) score at 24 weeks. Secondary endpoints will also be measured at 24 weeks, including change from baseline in slow vital capacity, muscle strength, quality of life measurements as well as additional signs of disease progression. 

If you are a patient (PALS) or caregiver of someone with ALS (CALS) and would like more information, please visit: https://seelostherapeutics.com/patients-and-caregivers/

About SLS-005 (trehalose injection, 90.5 mg/mL for intravenous infusion)

SLS-005 is a low molecular weight disaccharide (0.342 kDa) that crosses the blood brain barrier and is thought to stabilize proteins and activate autophagy through the activation of Transcription Factor EB (TFEB), a key factor in lysosomal and autophagy gene expression.  Activation of TFEB is an emerging therapeutic target for a number of diseases with pathologic accumulation of storage material. In animal models of several diseases associated with abnormal cellular protein aggregation or storage of pathologic material, SLS-005 has been shown to reduce aggregation of misfolded proteins and reduce accumulation of pathologic material. SLS-005 has previously received Orphan Drug Designation for the treatment of ALS from the U.S. Food and Drug Administration and from the European Medicines Agency in the EU. SLS-005 is an investigational treatment and is not currently approved by any health authority for medicinal use.

About Amyotrophic Lateral Sclerosis (ALS)

According to the National Institute of Neurological Disorders and Stroke, amyotrophic lateral sclerosis (ALS) is a group of rare neurological diseases that mainly involve the nerve cells (neurons) responsible for controlling voluntary muscle movement. In ALS, both the upper motor neurons and the lower motor neurons degenerate or die and stop sending messages to the muscles. Unable to function, the muscles gradually weaken, start to twitch (called fasciculations), and waste away (called atrophy). Eventually, the brain loses its ability to initiate and control voluntary movements. The disease is progressive, meaning the symptoms get worse over time. The majority of ALS cases (90 percent or more) are considered sporadic. This means the disease seems to occur at random with no clearly associated risk factors and no family history of the disease. Although family members of people with sporadic ALS are at an increased risk for the disease, the overall risk is very low, and most will not develop ALS.

Most people with ALS eventually die from respiratory failure, usually within 3 to 5 years from when the symptoms first appear. However, about 10 percent of people with ALS survive for 10 or more years. Currently, there is no cure for ALS and no effective treatment to halt or reverse, the progression of the disease.

Forward Looking Statements

Statements made in this press release, which are not historical in nature, constitute forward-looking statements for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements include, among others, those regarding Seelos’ Registrational Phase II/III Trial of SLS-005 treatment of ALS  (the “Trial”), the number of patients to be enrolled in the Trial, the expected duration of the Trial, the primary and secondary endpoints to be evaluated in the Trial and statements regarding SLS-005’s prospects and statements regarding the Company’s potential market opportunity. These statements are based on Seelos’ current expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Risks associated with Seelos’ business and plans described herein include, but are not limited to, the risk of not successfully executing its preclinical and clinical studies, or continuing its Trial, and not gaining marketing approvals for its product candidates, the risk that prior clinical results may not be replicated in future studies and trials (including the risk that the results from the prior studies of SLS-005 may not be replicated or may be materially different from the results of the Trial or other future trails and studies of SLS-005), the risks that clinical study results may not meet any or all endpoints of a clinical study and that any data generated from such studies may not support a regulatory submission or approval, the risks associated with the implementation of a new business strategy, the risks related to raising capital to fund its development plans and ongoing operations, risks related to Seelos’ current stock price, risks related to the global impact of COVID-19, as well as other factors expressed in Seelos’ periodic filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, even if subsequently made available by us on our website or otherwise. We do not undertake any obligation to update, amend or clarify these forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

Contact Information:

Anthony Marciano
Chief Communications Officer 
Seelos Therapeutics, Inc. (Nasdaq: SEEL)
300 Park Ave., 2nd Floor 
New York, NY 10022
(646) 293-2136
anthony.marciano@seelostx.com 
https://seelostherapeutics.com/
https://twitter.com/seelostx 
https://www.linkedin.com/company/seelos

Mike Moyer Managing Director
LifeSci Advisors, LLC
250 West 55th St., Suite 3401 
New York, NY 10019
(617) 308-4306
mmoyer@lifesciadvisors.com

SOURCE Seelos Therapeutics, Inc.

Posted on

Making psilocybin for 1/100th the price

Vancouver discovery will make ‘Magic Mushroom’ mental health care cheaper

Producing psilocybin is wildly expensive if you want it to meet the FDA’s Good Manufacturing Practice (GMP) standards. With all the testing required, it can cost $7,000-$10,000 for a single gram of psilocybin.

Core One Labs (COOL) developed a new production method involving fermentation of bacteria that could reduce the cost of production to under $100 per gram. 

Hopefully this will make psilocybin therapy much more affordable!

PDF of article

Posted on

World’s First clinical trial for DMT-assisted therapy in Major Depressive Disorder Shows Consistent Quality of Psychedelic Response in Phase I

World’s First clinical trial for DMT-assisted therapy in Major Depressive Disorder Shows Consistent Quality of Psychedelic Response in Phase I

In the Phase I clinical trial, participants were administered SPL026 and underwent a 20-minute psychedelic experience

Phase I full dataset demonstrates consistent dose related effects on the intensity and quality of the psychedelic experience

February 22, 2022 – London, United Kingdom – Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a neuropharmaceutical company focused on psychedelic-assisted N,N-dimethyltryptamine (“DMT”) therapies for mental health, is pleased to share the analysis of Phase I data from the combined Phase I/IIa clinical trial of SPL026 with psychotherapy for the treatment of Major Depressive Disorder (“MDD”).

In the dose-escalating, placebo-controlled Phase I study, 32 healthy psychedelic naïve volunteers across four dose cohorts received either SPL026 in combination with psychotherapy (n=24) or placebo (n=8). This analysis provides additional insight into dose-related effects on the primary outcomes of safety and tolerability as well as on pharmacodynamic measures, including the treatment experience and subject well-being.

Dr. Carol Routledge, Chief Medical and Scientific Officer of Small Pharma said:

The analysis of the unblinded data set supports our choice to explore the antidepressant potential of our selected dose of SPL026 in the Phase IIa trial. Given the subjectivity of the psychedelic experience, it was exciting to see a close correlation between levels of drug in the body and pharmacodynamic endpoints. As for the subjects’ experience, most reported that it was pleasurable, not too challenging, and most importantly, nobody expressed any regrets. Additionally, the strong safety profile and rapid clearance of SPL026 from the body provides the potential for a scalable treatment with limited monitoring needs post dosing.”

Key Results

  • No drug-related serious adverse events and minimal short-lived adverse events reported on dosing day.
  • Of 20 drug-related adverse events, all were mild (85%) or moderate (15%) and resolved rapidly and independently.
  • No statistically significant negative effects on anxiety and well-being identified at any point during the three-month follow-up.
  • Data show a clear correlation between quality of psychedelic experience and dosing levels, starting at 9mg and up to 21.5mg, across all four cohorts.
    • Participant-reported scores, using a 0 to 100 scale, on the richness of the psychedelic experience demonstrated increasing values of 48 (9mg), 79, 79, 88 (21.5mg) across the four increasing doses. A dose correlation was seen across most patient-reported scores.
    •  Therapist assessment of the predicted therapeutic benefit of SPL026 demonstrated a positive relationship with dose.
  • In the majority of participants, there was a strong correlation between levels of N,N-dimethyltryptamine (“DMT”) in the body and the quality and intensity of the psychedelic experience.
  • IV administration of SPL026 offers a short-lived, well-tolerated psychedelic experience of ~20 minutes, enabling a dosing session to last only ~30 minutes.
  • Pharmacokinetic sampling supported rapid clearance out of the body, showing near undetectable DMT levels in the blood by 60 minutes at all investigated doses.

The data confirms the selected dose of SPL026 taken forward into Phase IIa most consistently delivers the target treatment profile across subjects through a multi-dimensional assessment including safety, tolerability, pharmacokinetic and pharmacodynamic parameters. The full dataset is anticipated to be published in a peer reviewed journal.

David Erritzoe of Imperial College London, Chief Investigator of the Phase I/IIa study said:

Psychedelic-assisted therapies have the potential to completely change the treatment paradigm of mental health conditions. The additional insights from Small Pharma’s Phase I study show promising results at this stage of the development. The dosing time of 30 minutes, in comparison with up to 6 hours seen with alternative approaches, has the potential to offer a real benefit in terms of treatment regimen for both patients and providers.”

The blinded, randomized, placebo-controlled, proof-of-concept Phase IIa study of SPL026 in combination with psychotherapy in 42 patients with MDD remains on track to deliver topline results in the first half of 2022. This study will assess the efficacy of one dose of SPL026 versus a placebo, and one versus two doses of SPL026 in combination with psychotherapy in patients with MDD while bolstering existing safety and tolerability data. About Small Pharma

Small Pharma is a neuropharmaceutical company specialized in IP led development of novel treatments for mental health conditions, with a focus on depression. Small Pharma initiated a clinical program into DMT-assisted therapy in February 2021. This program includes a Phase I/IIa trial on its lead candidate, SPL026, alongside development of a robust pipeline of proprietary preclinical assets.

About DMT 

DMT is a naturally occurring psychedelic tryptamine found in plants and in the brain of mammals. Scientific evidence suggests DMT offers the potential for rapid-acting and long-lasting antidepressant effects. DMT is differentiated by its short psychedelic experience (<30mins), which allows for short treatment sessions and offers the potential for convenient supervised treatments within patient clinics. Small Pharma is advancing a pipeline of DMT-based therapies and is leading the world’s first DMT clinical trial for depression, in collaboration with Imperial College London.

For further information contact: Small Pharma

Peter Rands
Chief Executive Officer
Email: ir@smallpharma.co.uk
Tel: +44 (0)20 7112 9118

Investor Relations Contacts:

Eric Ribner
LifeSci Advisors
Email: eric@lifesciadvisors.com
Tel: +1 (646)-889-1200

Tim Regan
KCSA Strategic Communications
Email: smallpharmair@kcsa.com
Tel: +1 (347) 487-6788

Media Relations Contacts:

USA
McKenna Miller
KCSA Strategic Communications
Email: smallpharmapr@kcsa.com
Tel: +1 (949) 949-6585

Rest of World
Donna Curran
Hanover Communications
Email: dcurran@hanovercomms.com
Tel: +44 (0)20 7400 4480

Cautionary Note Regarding Forward-Looking Statements

This press release contains statements that constitute “forward-looking information” (“forward-looking information”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking information and are based on expectations, estimates and projections as at the date of this news release. Any statement that discusses predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking information. Forward-looking statements in this news release include statements regarding the Company’s continued progress in Phase I/IIa clinical trial of SPL026, the anticipated timing for the readout of topline data for the Company’s Phase IIa trial, the Company’s advancement of pre-clinical trials into new clinical trials, including the anticipated commencement and timing of the Company’s Phase IIb trial of SPL026, the Company’s success in launching a clinical program into DMT-assisted therapy, the Company’s ability to develop solutions to effectively address depression through DMT-based therapies, the potential of DMT-assisted therapies to transform the lives of patients suffering with MDD, the ILAP providing potential access to speedier time to market and facilitation of patient access to emerging and novel treatments, and the Company’s development of a robust pipeline of proprietary preclinical assets. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, it can give no assurance that the expectations of any forward-looking information will prove to be correct. Known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking information. Such factors include, but are not limited to: compliance with extensive government regulations; domestic and foreign laws and regulations adversely affecting the Company’s business and results of operations; the impact of COVID-19; and general business, economic, competitive, political and social uncertainties. Accordingly, readers should not place undue reliance on the forward-looking information contained in this press release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking information to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking information or otherwise.

Small Pharma makes no medical, treatment or health benefit claims about its proposed products. The U.K. Medicines and Healthcare products Regulatory Agency (“MHRA”)or other similar regulatory authorities have not evaluated claims regarding DMT-assisted therapies and other next generation psychoactive compounds. The efficacy of such therapies has not been confirmed by MHRA-approved research. There is no assurance that such DMT-assisted therapies and other psychoactive compounds can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. Any references to quality, consistency, efficacy and safety of potential therapies do not imply that Small Pharma verified such in clinical trials or that Small Pharma will complete such trials. If Small Pharma cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Small Pharma’s performance and operations.

The TSX Venture Exchange (the “TSXV”) has neither approved nor disapproved the contents of this news release. Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

Posted on

Core One Labs’ Files Milestone Patent for Protection of its Recombinant Production System for Optimized Biosynthetic N-methyltryptamine (NMT)

Core One Labs’ Files Milestone Patent for Protection of its Recombinant Production System for Optimized Biosynthetic N-methyltryptamine (NMT)

Vancouver, British Columbia, Canada – February 21, 2022 – Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (“Core One” or the “Company”) is pleased to announce that its wholly-owned subsidiary, Vocan Biotechnologies Inc. of Victoria, British Columbia, has filed a patent application with the United States Patent and Trademark Office (“USPTO”) for the production of biosynthetic N-methyltryptamine (NMT) (also known as monomethyl tryptamine (MMT)) through its optimized recombinant production system (the “System”). N-Methyltryptamine is a member of tryptamines and is an organic compound known to produce psychoactive effects when combined with a monoamine oxidase A inhibitor (MAOI).[1]

The patent entitled “Production of Psychedelic Compounds” protects Core One’s novel proprietary production system. The System, under the leadership of Dr. Jan Burian, Chief Scientist, and Dr. Robert EW Hancock, is designed to make bacteria act as a biological factory and produce bioidentical psychedelic analogs such as biosynthetic N-methyltryptamine (NMT).

The Company’s unique production process can manufacture a more superior cGMP compliant API grade NMT (or other psychedelic products) than any chemically synthesized counterpart, since it retains the stereochemistry of the natural psychedelic analogs found in hallucinogenic mushrooms. Natural psilocybin and psychedelic-related molecules are known to have a more positive effect than those chemically synthesized; however, analog compounds can potentially be more effective and safer than natural compounds.

A final patent approval would propel Core One past industry rivals since their game-changing production process enables mass-production of synthetic psilocybin and other psychedelic compounds or analogs more rapidly, while also reducing the production cost and market price drastically. It also maintains the quality and efficacy that are usually present in organically produced psychedelics.

“Filing this patent is an important milestone for the company since it allows us to protect our intellectual property against potential competitors. The patent provides a broad array of strategies useful for making psychedelic compounds enabling Core One to diversify its product portfolio,” stated Dr. Bob Hancock, CEO of Vocan Biotechnologies.

ABOUT CORE ONE LABS INC.

Core One is a biotechnology research and technology life sciences enterprise focused on bringing psychedelic medicines to market through novel delivery systems and psychedelic assisted psychotherapy. Core One has developed a patent pending thin film oral strip (the “technology”) which dissolves instantly when placed in the mouth and delivers organic molecules in precise quantities to the bloodstream, maintaining excellent bioavailability. The Company intends to further develop and apply the technology to psychedelic compounds, such as psilocybin. Core One also holds an interest in medical clinics which maintain a combined database of over 275,000 patients. Through these clinics, the integration of its intellectual property, R&D related to psychedelic treatments and novel drug therapies, the Company intends to obtain regulatory research approval for the advancement of psychedelic-derived treatments for mental health disorders.

CORE ONE LABS INC.

Joel Shacker

Chief Executive Officer

FOR FURTHER INFORMATION:

Email: info@core1labs.com

Telephone: 1-866-347-5058

FOLLOW US:

Website: https://core1labs.com/

Twitter: https://twitter.com/Coreonelabs

Facebook: https://www.facebook.com/Core-One-Labs-Inc-100969251278277/

LinkedIn: https://www.linkedin.com/company/core-one-labs

Instagram: https://www.instagram.com/coreonelabsinc/

CAUTIONARY DISCLAIMER STATEMENT

The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management’s current estimates, beliefs, intentions, and expectations. They are not guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain, and that actual performance may be affected by a number of material factors, many of which are beyond the Company’s control. Such factors include, among other things: risks and uncertainties relating to the Company’s limited operating history and the need to comply with strict regulatory regulations. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.

In addition, psilocybin is currently a Schedule III drug under the Controlled Drugs and Substances Act (Canada) and it is a criminal offence to possess substances under the Controlled Drugs and Substances Act (Canada) without a prescription or authorization. Health Canada has not approved psilocybin as a drug for any indication. Core One does not have any direct or indirect involvement with illegal selling, production, or distribution of psychedelic substances in jurisdictions in which it operates. While Core One believes psychedelic substances can be used to treat certain medical conditions, it does not advocate for the legalization of psychedelics substances for recreational use. Core One does not deal with psychedelic substances, except within laboratory and clinical trial settings conducted within approved regulatory frameworks.

[1] Foye’s principles of medicinal chemistry By William O. Foye, Thomas L. Lemke, David A. Williams

Posted on

Ai creates new state of consciousness for crime prevention: issue 37

Hello and welcome back.

Happy Fungi Friday 🎉 Whether you swear by the benefits of microdosing or you’re convinced it’s a placebo, get ready for research to confirm your beliefs 🙃

Here’s what’s in store for you in today’s issue:

🍄 The company that’s designing brand new states of consciousness

🍄 Can psilocybin treat the deadliest mental health disorder?

🍄 The effects of different microdosing regimens

🍄 How patients feel 1 year after psilocybin therapy

🍄 And more.

Be sure to check out this week’s Daily Mushroom podcast:

Michael Kydd opens up about the impact of losing his mother at a young age

On this episode of the Daily Mushroom Podcast, we have Michael Kydd, an independent consultant helping psychedelic companies navigate the complex world of government relations. in this emotional episode, Michael talks about his experience with the passing of his mother, and how he believes psychedelics could have strongly benefited his mothers and his family in that difficult time. 

Therapeutic banner

Can psilocybin treat the deadliest mental health disorder?

Anorexia has a higher mortality rate than any other psychiatric condition, as patients have a high risk of death by both suicide and organ failure.

Current treatments work for less than half of patients, which is why Imperial College London is preparing to study psilocybin therapy as an alternative. 

The school is recruiting female patients who have had a diagnosis for at least 3 years and have tried other forms of treatment without success. They’ll each receive 3 doses of psilocybin, and researchers will use several MRIs and EEG scans to understand the effects of the treatment.

Is microdosing a placebo? 💊

This week, Nova Mentis (NOVA) announced that rats with cognitive impairments saw improvements in memory when given a microdose of psilocybin every other day for just two weeks.

However, a new University of Chicago study found no effect on mood or task performance after giving healthy volunteer 4 LSD microdoses 3-4 days apart in a placebo-controlled study.

Could it be that a more frequent dose is needed to see benefits? Or is psilocybin faster acting than LSD? Or maybe microdosing is a placebo after all.

Stay tuned as we follow along with the latest research. 

Depression free for 1 year

Johns Hopkins researchers found that one year after receiving psilocybin therapy, 75% of patients sustained significant reductions in depression scores and 58% no longer qualified for a diagnosis. 

However, about a third of patients also used traditional antidepressants and 42% received additional psychotherapy at some point during the year.

So although psilocybin therapy can have rapid results, multiple treatment options can help sustain the benefits.

Making microdoses even safer

One of the few concerns that experts have about microdosing is the long term impact on heart health. Psilocybin binds to 5-HT2B receptors, which could increase risk of heart valve disease with frequent use. 

Mydecine (MYCO) developed a group of patent-pending molecules that bind only to 5-HT2A receptors, making them safer for microdosing. The company aims to administer these compounds through a microdosing patch to eliminate another side effect: nausea. 

inspirational banner

Shroom use →  less crime

People who use shrooms are less likely to commit crimes, according to new research.

An analysis of The National Survey on Drug Use and Health found that psilocybin use is linked to significantly reduced odds of arrest for:

  • Larceny
  • Burglary & robbery
  • Simple assault & battery
  • Serious violence
  • DUI
  • And other miscellaneous crimes

LSD appeared to have no impact on crime rates 🤔

Brand new states of consciousness

Mindstate Design Labs raised $11.5M in seed funding to create “new novel states of consciousness that just don’t exist yet.”

The company is taking a reverse approach to drug discovery. Researchers will design a unique state of mind first and then create a compound that can get you there. 

How? Using predictive AI technology, subjective data from 7,000+ trip reports, and biochemical data on how different molecules interact with receptors in the body. 

Who’s brave enough to test out a brand new state of mind?

Introducing Houston, your new microdosing companion

Houston is an app that helps you set intentions, track doses and moods, dose with community, and more, on your journey through inner space.

“Took a dive into Houston just now and WOW, absolutely phenomenal. User friendly, knocks out everything I journal while I’m microdosing, love intention section and the playlists. Wow. I am beyond elated you found me,” says one user.

Download Houston on the App Store and follow their Instagram to see when they launch on Android.

Get a Master’s in mushrooms

Vancouver Island University is launching a psychedelic-assisted therapy graduate certificate program this September, becoming the first accredited school in Canada to offer such a program.

A company called Fluence will also be scaling psychedelic training for therapists in Oregon after completing a $3M seed funding round this week.

business banner

Entheon Biomedical (ENBI) initiated a ketamine study on depression in partnership with Wavepaths. It will monitor brain activity with EEG while assessing the impact of Wavepaths’ personalized music technology. 

Field Trip Health (FTRP) reported Q3 financial highlights including $74.5M in cash and patient services revenues of $1.36M, up more than 50% from Q2 and 330% year over year.

PharmaTher (PHRM) was granted a US patent for its formulation of ketamine and betaine anhydrous, a chemical that occurs naturally in the human body and may increase ketamine’s antidepressant effect. The formulation is already patented in Japan and Taiwan, and the company expects to receive patents in Europe, Canada, Israel and China in the near future.

Enveric Biosciences (ENVB) will partner with the University of Calgary to study oral psilocybin for cancer-related distress. Patient enrollment will begin by the end of this year or early next year.

legal banner

Here’s what you missed:

  • Hawaii senators unanimously passed a bill to create a psilocybin research task force and develop a long-term strategy to make treatments accessible and affordable. Read more…
  • With a 7-2 vote, Oklahoma legislators approved a bill in committee to decriminalize low-level possession of psilocybin and promote therapeutic research. Read more…

Video of the Week

Before & After Eating Magic Mushrooms to stop my Tremors

Playlist of the Week

LSD Trip | ACID Trip | Peaceful | Trippy
Posted on

The Chopra Foundation Announces Partnership with Cybin Inc. to Increase Education and Awareness of the Potential Use of Psychedelics in Supporting Well-Being and Mental Health

The Chopra Foundation Announces Partnership with Cybin Inc. to Increase Education and Awareness of the Potential Use of Psychedelics in Supporting Well-Being and Mental Health

– Cybin’s holistic and innovative approach to developing improved treatment options for patients aligns with the goals of the Foundation’s NeverAlone Initiative –

– Fireside chat featuring Deepak Chopra, M.D., FACP, The Chopra Foundation Founder, and Doug Drysdale, Cybin’s Chief Executive Officer, scheduled for Wednesday, February 23, 2022 at 12:00 p.m. ET – 

February 15, 2022– The Chopra Foundation (the “Foundation”), a not-for-profit organization founded by Dr. Deepak Chopra, dedicated to improving health and well-being, today announced a partnership with Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) (“Cybin”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™”. The Foundation is working closely with Cybin to support education and awareness about its groundbreaking research to harness the potential of psychedelic therapies in mental health. Emerging research shows that psychedelic-assisted therapy can potentially improve the quality of life for people suffering with mental illnesses, including those specific indications that Cybin is targeting, such as Major Depressive Disorder, Alcohol Use Disorder and Anxiety Disorders.

“The need for new and more effective treatments across the mental health spectrum is more urgent today than ever. Through our NeverAlone movement, we aim to combine forces with the best and brightest across businesses, policymakers, mental health professionals, and others – all with the goal of building awareness, advancing scientific research, and creating a global community to ensure widespread access to well-being resources. As the number of companies pursuing psychedelic-based therapies continues to grow, the Foundation is particularly excited about partnering with Cybin based on its commitment to global well-being and mental health,” said Dr. Deepak Chopra, The Chopra Foundation Founder, Chairman of the Board and Director. 

The Chopra Foundation is dedicated to improving the world’s well-being, cultivating spiritual knowledge, expanding consciousness, and promoting world peace to all members of the human family. The Foundation’s NeverAlone Initiative is focused on reframing the conversation around mental health by forging an alliance of people and organizations dedicated to lighting the path for the world to proactively pursue joy, the ultimate measure of well-being.

“Cybin has cultivated a leadership position in this space based on their proprietary scientific approach that delivers the healing properties of classic psychedelics while reducing variable side effects that have prevented these natural compounds from becoming therapies in the past. This differentiated method is thoughtful and ethical and Cybin is one of the only companies that may truly address the needs of patients and providers. Their vision for improving the landscape of mental illness perfectly aligns with our goals and we look forward to a productive partnership to further both of our missions,” concluded Dr. Chopra.

Cybin’s team of talented industry experts and scientists are working to bring revolutionary psychedelic-based treatment options to patients in need. Cybin’s core values center on its holistic approach to therapeutics and its commitment to transforming the standard of care in mental health.

In addition to its ongoing preclinical, clinical and investigative drug development programs, Cybin shares the Foundation’s commitment to ensuring access to well-being resources for all, including those in underserved communities. 

“We are honored to partner with The Chopra Foundation, and specifically, to be part of the NeverAlone Initiative. Much is understood about psychedelics, as they have been studied in academia for decades, but there is still much investigative work to be done. At Cybin, we are using medicinal chemistry and drug delivery technologies to build on existing clinical data and improve the patient experience by overcoming the limitations of current treatments for mental illness. We share the Foundation’s pioneering spirit with regard to mental health and well-being and its goal of ensuring accessibility to much-needed treatment options to those in need,” said Doug Drysdale, Cybin’s Chief Executive Officer.

The Chopra Foundation and Cybin plan to host a fireside chat featuring Dr. Chopra and Mr. Drysdale to discuss the current status and future of psychedelics as therapeutics on Wednesday, February 23, 2022 at 12:00 p.m. ET. To register for online access to the fireside chat, please click here.

About The Chopra Foundation and Never Alone

The Chopra Foundation is a 501 (c) (3) organization (#36-4793898) dedicated to improving health and well-being, cultivating spiritual knowledge, expanding consciousness, and promoting world peace to all members of the human family. The Foundation’s Never Alone movement will be providing the world with the tools to proactively pursue their path to joy and freedom from suffering.

Media Inquiries:

Kristen Marion

kristen@marionpr.com

623-308-2638